TGFα also induced many changes typical of OA in cultured rat chondrocytes 5 . The locus identified by Zengini et al. therefore reinforces the idea that TGFα might be an important cytokine in OA.
Another newly associated SNP 3 was located in an intron of MAP2K6, which encodes dual specificity mitogen-activated protein kinase (MAPK) kinase 6 (MP2K6), a central member of the p38 MAPK pathway. This pathway is involved in the signal transduction of a plethora of cellular processes, including inflammation and chondrocyte apoptosis, and its inhibition has been proposed to be beneficial for OA. However, the overall inhibition of the p38 MAPK pathway has resulted in aggravated disease in mouse models of OA 6 . The possibility that MP2K6 could provide clues about how to modulate the p38 MAPK pathway in a selective and beneficial way merits additional studies.
The third promising gene, BACH1, is located in the vicinity of another newly associated SNP, rs116882138, and showed increased RNA expression in degraded carti lage 3 . Previous mouse studies have shown that deficiency of Bach1 prevents the development of OA by a combination of reduced oxidative damage and decreased amounts of extra cellular matrix-degrading enzymes 7 , suggesting that this locus could be the first to be related to reactive oxygen species in OA.
Understanding the genetic relationships between OA and other traits or clinical conditions can help elucidate cause and effect, as inherited genetic risks cannot be subject to reverse causation. To this end, Zengini and co-workers 3 investigated the genetic relationship between OA and other traits using two methods. First, they estimated genetic correlations using cross-trait linkage disequili brium score regression to assess the heritability explained by common SNPs. This method distinguishes between population stratification and polygenicity in GWAS 8 . 
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traits (Box 1). In other words, genetic factors that predispose to various measures of obesity also cause an increased risk of OA, a fact that had previously been reported in smaller data sets than those used by Zengini et al. 3 and only for a single obesity-related gene 2 . Interestingly, Zengini et al.
3 did not find a causal effect between metabolic syndromerelated phenotypes (other than obesity) and OA, although an association between metabolic syndrome and OA has been postulated 10 . These data are relevant as they suggest that although there are likely to be common pathogenic pathways between traits such as dyslipidaemia and OA or type 2 diabetes mellitus and OA, these conditions do not seem to be causally linked.
In conclusion, this truly large-scale GWAS 3 confirms the complexity of OA at a genetic level and provides some clues that could help to define the molecular pathogenesis of this disease. Among these clues, genetic factors related to obesity but not to other aspects of metabolic syndrome are important as causative contributors to OA in large joints. 
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RNA sequencing and machine learning as molecular scalpels
Myles J. Lewis and Michael R. Barnes
The application of new technologies including RNA sequencing and machine learning to the analysis of synovial tissue is yielding new insights into the pathology of rheumatoid arthritis, with potential implications for the clinical management of the disease. Machine learning offers an opportunity to integrate detailed knowledge of disease processes with omics data. To set up a machine learning model, Orange et al. 2 assessed the histo logical features of synovial tissue obtained from patients undergoing joint replacement surgery (123 patients with RA and 6 patients with osteoarthritis (OA)). Robust histological features were selected on the basis of features that were most common and could be consistently identified by different pathologists. Tissue RNA-seq was performed on a subset of 45 synovial samples (39 RA and 6 OA), and consensus clustering suggested the existence of three expression subtypes: low and mixed inflammatory subtypes observed in patients with either RA or OA and a high inflammatory subtype found exclusively in patients with RA. The investigators used the selected histology features to predict the expression subtype of the remaining 78 individuals using a form of machine learning, known as a support vector machine (SVM), which was trained on the 45 sequenced samples.
The findings from the developed SVM model brought some new insights; for example, the most informative predictor of the high inflammatory subtype was the presence of plasma cells, whereas pain scores correlated with C-reactive protein in patients with the high inflammatory subtype, but not in patients with the low inflammatory subtype, implying the existence of different pain drivers between the high and low inflammatory subtypes. However, it should be noted that SVM training is prone to overfitting (that is, the model might use random noise in the data in an overly complex and non-reproducible manner) in data sets of small sample sizes, and despite the use of cross-validation training, the study lacked external validation. Additionally, the patients had an average disease duration of 14 years and so probably had received past treatment with multiple therapies (indeed, 53% of the patients received a biologic agent before surgery), which might have confounded findings. Orange and colleagues proposed that their SVM algorithm could be used in place of gene expression biomarkers to identify the three inflammatory subtypes and would be cheaper and more widely applicable than using omics platforms. This step seems to counter the prevailing 'omics revolution' (that is, the drive to use omics platforms in clinical practice), but might offer a middle road to bring omics which were located in the intimal lining by histology, and CD90 + fibroblasts, which were further subdivided into type 2a and type 2b and were located in the synovial sublining.
Although tissue RNA-seq arguably offers only incremental advantage over microarray studies, at increased cost, Stephenson et al. demonstrate the revolutionary potential of scRNA-seq and the reproducibility between re-aggregated scRNA data and tissue RNAseq. scRNA-seq can unveil the unique picture of the transitions between cell states that characterize the cellular immune response. Furthermore, this technology can differentiate gene expression dynamics that are masked in bulk, population-averaged measurements 6 . Intriguingly, scRNA-seq is also sensitive to genome variation, enabling the detection of discontinuous transcription, or 'bursting' , thus enabling the measurement of both the frequency of such bursts of expression and the magnitude of expression in a manner that is undetectable in tissue 6 . Even though microfluidic approaches remain under development, a technical risk of these approaches, considering the limited stability of RNA, includes RNA degradation and cell lysis, which could compromise cellular transcriptome analysis and jeopardize finite patient biopsy material needed to accurately study RA pathophysiology. As microfluidic instrumentation continues to develop, along with scRNA analysis methodology, we anticipate that the single-cell approach could become the method of choice for transcriptomic analysis. However, there is currently no consensus on the technical and analytical processes required for such an analysis 7 , supporting a continuing focus on bulk tissue material, perhaps with complementary scRNA-seq studies in the same samples.
insights into clinical environments where omics technologies are unavailable.
In an alternative approach to improving the accessibility of omics technologies, Stephenson et al.
3 developed a low-cost, 3D-printed microfluidic instrument that can perform single-cell transcriptome profiling. With this technology, the investigators presented an intriguing molecular view of the synovium by disaggregating synovial tissue from five patients with RA, again obtained during joint surgery, to sequence 20,387 single cells. On average, 29,651 reads were generated per cell, enabling the detection of 2,315 different mRNA species per cell on average (~10% of the transcriptome). The clustering of individual cellular transcriptomes enabled the detection of 13 distinct clusters that apparently represented distinct autoimmune cell infiltrate and stromal cell populations, including new and distinct fibroblast populations. Although the data set is probably not the comprehensive 'cell atlas' of the RA synovial tissue that the investigators claim, the methodology could certainly be applied to create such a resource.
Technologically, the method from
Stephenson and colleagues is impressive and apparently successful. The manufacturing protocols are provided in an open protocol repository and should enable others to construct microfluidic devices using widely available 3D printer technology at a much lower cost than sourcing commercial alternatives. Although preliminary, this study brings potentially important insight into the structure of synovial tissues by the identification of three transcriptionally distinct fibroblast subpopulations, which could be distinguished in terms of their CD55 and CD90 surface expression: CD55+ fibroblasts (called type 1 in this study), To discover novel and relevant biomarkers using omics technologies, a number of key aspects should be considered in the design of the experiment. These aspects include the type of clinical data collected, the tissue types investigated and the technologies and algorithms used.
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In order to understand the complex interplay between infiltrating immune cells and disease-altered stromal cells in inflamed synovium, future studies will need to build on these pioneering studies in many areas (Fig. 1) . Although the studies by Orange et al. and Stephenson et al. understandably focused on synovial tissue obtained during joint replacement surgery, such tissue samples are unrepresentative of RA pathology, particularly the clinically important early stages of the disease. Performing synovial biopsies in treatmentnaive patients will be crucial for distinguishing inflammation in reaction to ongoing joint damage from inflammatory mechanisms driving disease processes. Biopsies performed before treatment with steroids, DMARDs or biologics might reveal stronger signals that can differentiate true disease endotypes, just as biopsies for classifying lymphoma are best performed before steroid treatment 8 .
In terms of measuring disease activity, obtaining accurate clinical data that incorporate ultrasound and radiographic imaging will enable a more objective estimation of disease burden compared with disease activity measures that rely on subjective patient measures such as pain scores and tender joint count. The integration of data from multiple omics platforms into measurements of disease activity will provide increased depth of knowledge of the disease process in RA. However, with the massive expansion in data, more refined, standardized, machine learning algorithms that are suited to heterogeneous, high-dimensional and statistically noisy data sets will be required. The lack of consensus surrounding the best approaches for analysing data remains a barrier. Furthermore, true validation of biomarkers identified by multiomics studies will require carefully collected replication cohorts as standard practice.
